Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Hmmm... Echelon buying WTs, Institutions holding or buying..
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(117)
•••
Comment by gojotv!on Apr 13, 2021 4:52am
106 Views
Post# 32983292

RE:RE:RE:RE:RE:Hmmm... Echelon buying WTs, Institutions holding or buying..

RE:RE:RE:RE:RE:Hmmm... Echelon buying WTs, Institutions holding or buying..This deal isn't "dilutive" AT ALL. It's an acquisition.
"Dilution" is when shares are added to the pool, but the company remains the same. Then, each share represents a smaller portion of the company.
If you have twice the company for 25% more shares, each share actually grows in value!
It's the opposite of dilution!
"Dilution is one of the BIG LIES the bashers put out over and over, and I HAVE already addressed it in my posts.
That tells me that, either you're not paying attention, or you're part of this basher disinformation effort, hoping to repeat the lie until it is adopted as truth.
Very sneaky tactic, if that's what you're up to.

 
Eagles1968 wrote: Good points. There is only one analyst. Don't worry about anyone else saying 30 or 40 cents. I agree with you there. But this deal is very dilutive so I am not sure why u aren't mentioning that. Why not do a deal with care oncology and give them a fee. Get option to buy the company if the strategy is successful. No reason to buy them at this stage at all. My guess is this deal doesent go through but who knows for sure.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities